FDA Fast-Tracks Review of Psychedelic Drugs for Mental Health Treatment

Fri Apr 24 2026 16:03:16 GMT+0000 (Coordinated Universal Time)

In a significant policy shift, the FDA under the Trump administration is accelerating the review process for three psychedelic drugs, reinforcing support from various political factions for these treatments.

The FDA has announced a priority review process for three psychedelic drugs intended for treating mental health conditions, a move following President Trump's recent executive order. The decision could pave the way for broader acceptance and use of psychedelics in psychiatry, as public support for such treatments grows. The focus is on psilocybin for depression and MDMA for PTSD, with the administration aiming to address challenges in mental health through innovative approaches.

In a marked shift towards embracing alternative mental health treatments, the Food and Drug Administration (FDA) has announced it will expedite the review process for three psychedelic drugs aimed at treating mental health conditions such as depression and PTSD. This initiative reflects the Trump administration's efforts to revolutionize mental health treatment, aligning with the growing public sentiment favoring the integration of psychedelic therapies.

Recently, President Trump's executive order mandated federal agencies, including the FDA, to facilitate quicker access to psychedelics, which remain classified as illegal substances under federal law. The FDA has designated priority review vouchers for two firms studying psilocybin, the principal component of magic mushrooms, along with another company focused on MDMA for PTSD. Although the companies are not publicly named in the announcement, the expedited reviews are set to reduce typical timelines from months to a matter of weeks.

This policy shift highlights an increased demand for effective treatments in mental health, particularly from factions of Trump’s supporter base, including veterans who advocate psychedelic therapies as potential solutions for trauma and PTSD.

Activists and supporters, particularly those in the Make America Healthy Again movement, spearheaded by Public Health Secretary Robert F. Kennedy Jr., express optimism about these developments. Kennedy has even pledged to make psychedelics broadly available for challenging psychiatric conditions within the year.

As the FDA plans to authorize further testing on related compounds, such as ibogaine—known for its controversial use to treat addiction—Congressional oversight is expected to intensify, particularly regarding the agency’s expedited review processes. Critics point to potential biases in the approval process, as certain companies may be favored by political affiliations.

The engagement of influential figures such as podcaster Joe Rogan, who has publicly endorsed psychedelics, further underscores the intersection of health policy and political strategy.

As the landscape of clinical psychiatry evolves, the implications of psychedelics in mental health treatment are being revisited, marking a possible era of legislative and cultural transformation surrounding drug policy in the United States.